Biological agents targeting interleukin-13 for atopic dermatitis.
Andrea ChiricozziNiccolò GoriMartina MaurelliPaolo GisondiGiacomo CaldarolaClara De SimoneKetty PerisGiampiero GirolomoniPublished in: Expert opinion on biological therapy (2022)
Biological agents that neutralize IL-13 have demonstrated clinical benefits in treating AD with excellent safety profiles. Robust clinical evidence exists in support of tralokinumab, which underwent phase III trials, met the predefined primary endpoints, and is approaching the market. In contrast, clinical trial testing for lebrikizumab needs to be completed to fully assess its therapeutic potential.